Ann: Positive Top-Line Results in DKD Phase 2 Clinical Study, page-214

I am not a medical person, read the ann carefully and although it did not reflect the excitement of the headline
realised that there was real benefit to be found in the results. Expectations were high and not prepared for anything less,
However Dr B and Ovf, you have both given a balanced and realistic outlook on results, and I also believe that there
would be enough to interest a partnership deal. To sell at this point (especially if at a loss) seems ridiculous because
much more potential here apart from this trial, and if prepared to be patient, profits still to be made. I realise that funds
to cover more research are important, but I still believe the most important outcome of this trial is the fact that sick people
can benefit from the drug. I also wonder about the share dump just before the ann which seems unusual if no prior
knowledge of ann. Anyhow hope some sanity will prevail and shareholders will again see the value here which is
definitely above the SP at present.